Ikena Oncology Shares Outstanding 2021-2025 | IMA
Ikena Oncology shares outstanding from 2021 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Ikena Oncology Annual Shares Outstanding
(Millions of Shares) |
| 2024 |
48 |
| 2023 |
42 |
| 2022 |
36 |
| 2021 |
28 |
| 2020 |
3 |
Ikena Oncology Quarterly Shares Outstanding
(Millions of Shares) |
| 2025-03-31 |
48 |
| 2024-12-31 |
48 |
| 2024-09-30 |
48 |
| 2024-06-30 |
48 |
| 2024-03-31 |
48 |
| 2023-12-31 |
42 |
| 2023-09-30 |
43 |
| 2023-06-30 |
39 |
| 2023-03-31 |
36 |
| 2022-12-31 |
36 |
| 2022-09-30 |
36 |
| 2022-06-30 |
36 |
| 2022-03-31 |
36 |
| 2021-12-31 |
28 |
| 2021-09-30 |
36 |
| 2021-06-30 |
36 |
| 2021-03-31 |
4 |
| 2020-12-31 |
3 |
| 2020-09-30 |
3 |
| 2020-06-30 |
3 |
| 2020-03-31 |
3 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.066B |
$0.009B |
|
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.
|
